{"gene":"TRIO","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2000,"finding":"Trio is essential for late embryonic development in mice; trio(-/-) embryos die between E15.5 and birth and display defects in secondary myogenesis (secondary myofibers absent, primary myofibers become aberrantly spherical) and aberrant organization in hippocampal and olfactory bulb regions, establishing Trio's roles in skeletal muscle formation and neural tissue organization.","method":"Mouse knockout (trio-/-), histology, genotype analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean loss-of-function mouse model with specific cellular phenotypes replicated across multiple tissues, published in a focused mechanistic study","pmids":["11050238"],"is_preprint":false},{"year":1999,"finding":"The amino-terminal GEF domain of Trio (GEF1) induces membrane ruffling, rapid cell spreading, haptotactic migration, and anchorage-independent growth when stably expressed in NIH 3T3 cells; the carboxy-terminal GEF domain produces a distinct lamellar/mini-ruffle phenotype. Full-length Trio also alters actin cytoskeleton organization and focal contact distribution in COS cells.","method":"Stable cell line expression of individual GEF domains, actin staining, haptotaxis assay, soft-agar anchorage-independent growth assay","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal cellular assays in a single lab, no in vitro biochemical reconstitution","pmids":["10341202"],"is_preprint":false},{"year":2008,"finding":"Trio mediates netrin-1-induced Rac1 activation via its interaction with the netrin-1 receptor DCC. Trio co-immunoprecipitates with DCC in mouse embryonic brains; Trio(-/-) cortical neurons fail to extend neurites in response to netrin-1; commissural axon guidance toward the floor plate is disrupted; anterior commissure is absent and netrin-1/DCC-dependent corpus callosum and internal capsule projections are defective in Trio-null embryos.","method":"Co-immunoprecipitation from embryonic brain, Trio(-/-) cortical neuron neurite outgrowth assay, spinal cord explant axon guidance assay, in vivo axon tract analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus multiple orthogonal loss-of-function assays (neuronal culture, explant, in vivo) in one study","pmids":["18212043"],"is_preprint":false},{"year":2005,"finding":"Drosophila Trio physically interacts with the Netrin receptor Frazzled (Fra) in GST-pulldown and co-immunoprecipitation assays. Mutations in trio dominantly enhance fra and Netrin mutant CNS commissure phenotypes; fra;trio double mutants show dramatic loss of commissural axons. Tyrosine phosphorylation of Trio is elevated when Abl kinase levels are increased in S2 cells. Heterozygosity for trio reduces ectopic midline crossing in Robo-Fra chimeric receptor embryos, placing Trio as an effector of Fra/Netrin signaling.","method":"GST-pulldown, co-immunoprecipitation, genetic epistasis (double mutants, dominant enhancement), S2 cell phosphorylation assay","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — physical interaction confirmed by two methods (GST pulldown + Co-IP) combined with genetic epistasis across multiple allele combinations","pmids":["15790972"],"is_preprint":false},{"year":2007,"finding":"The Rho-specific GEF domain of C. elegans UNC-73 (Trio ortholog) is a major Gαq effector. Forward genetic suppressor screens of hyperactive Gαq identified four mutations in the UNC-73 RhoGEF domain. UNC-73 RhoGEF loss phenocopies EGL-8 (PLCβ) loss (sluggish locomotion); double null of both genes phenocopies Gαq null (near-complete paralysis). Cell-based and biochemical assays show activated Gαq synergizes with Trio RhoGEF to activate RhoA, and activated Gαq co-immunoprecipitates with Trio RhoGEF.","method":"Forward genetic suppressor screen, double-mutant epistasis, cell-based Rho activation assay, co-immunoprecipitation, biochemical GEF assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — forward genetic screen + biochemical reconstitution + epistasis in one rigorous study","pmids":["17942708"],"is_preprint":false},{"year":2009,"finding":"ITX3, identified by screening for inhibitors of Trio's N-terminal GEF domain (TrioN/GEF1), selectively blocks TrioN-mediated Rac1 activation and dorsal membrane ruffling in mammalian cells without affecting GEF337-, Tiam1-, or Vav2-mediated GTPase activation. ITX3 inhibits endogenous TrioN activity and blocks NGF-stimulated neurite outgrowth in PC12 cells and C2C12 myotube differentiation, defining a Trio/RhoG/Rac1 signaling pathway.","method":"Chemical inhibitor screen, Rac1 activation assay, cell morphology/ruffling assay, neurite outgrowth assay, myotube differentiation assay","journal":"Chemistry & biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective small-molecule tool with multiple functional readouts in a single lab","pmids":["19549603"],"is_preprint":false},{"year":2003,"finding":"Trio binds focal adhesion kinase (FAK) via its SH3 domain (to FAK N-terminal domain) and kinase domain (to FAK kinase domain). Trio is constitutively tyrosine-phosphorylated; co-expression with FAK increases Trio in the detergent-insoluble fraction and causes co-localization at the cell periphery. FAK phosphorylates Trio at Y2737 in the kinase domain subdomain I. Trio reciprocally enhances FAK kinase activity in vitro and in vivo.","method":"Co-precipitation/co-immunoprecipitation, immunofluorescence co-localization, in vitro kinase assay, co-transfection, site identification by phosphopeptide mapping","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP + in vitro kinase assay in a single lab study","pmids":["12551902"],"is_preprint":false},{"year":2011,"finding":"A Trio-RhoA-Shroom3 pathway is required for apical constriction during lens pit invagination. Rock activity and RhoA activity are required for Shroom3-induced apical constriction; Trio was identified as the RhoA-GEF required for Shroom3-dependent apical constriction in both MDCK cells and the lens pit in vivo.","method":"Dominant-negative/constitutively active RhoA constructs, siRNA knockdown, lens-specific in vivo studies, Rock inhibitor treatment, epistasis","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown + constitutively active rescue + in vivo lens pit assay in a single lab","pmids":["22031541"],"is_preprint":false},{"year":2014,"finding":"A Trio-Rac1-Pak1 signaling axis drives invadopodia disassembly. A genetically encoded single-chain Rac1 FRET biosensor showed Rac1 activity exclusion from invadopodia cores and activation at invadopodia disappearance; photoactivation of Rac1 at invadopodia confirmed its disassembly role. Trio (TrioGEF) activates Rac1, which activates Pak1, leading to cortactin phosphorylation and invadopodia dissolution.","method":"FRET biosensor (live-cell imaging), Rac1 photoactivation, siRNA knockdown, cortactin phosphorylation assay","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — FRET biosensor plus photoactivation plus biochemical phosphorylation readout; multiple orthogonal methods in one study","pmids":["24859002"],"is_preprint":false},{"year":2014,"finding":"TRIO is phosphorylated at Y2681 by ABL tyrosine kinase downstream of a NOTCH-DAB1-ABL signaling cascade in colorectal cancer cells. pY2681 causes RHO activation; the unphosphorylatable TRIO Y2681F mutation reduces RHOGEF activity and inhibits invasion of colorectal cancer cells, establishing Trio as a downstream ABL substrate that transduces NOTCH signaling to RhoA-mediated invasion.","method":"Genetic depletion (knockout mice), phospho-specific antibody detection, unphosphorylatable mutant (Y2681F) functional assay, ABL inhibitor treatment, invasion assay","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — phospho-site identified, unphosphorylatable mutant used for functional rescue, in vivo genetic validation, multiple orthogonal approaches","pmids":["25432929"],"is_preprint":false},{"year":2015,"finding":"Suppression of endogenous TRIO in dissociated rat hippocampal neurons enhances dendritic formation, and decreasing TRIO in organotypic hippocampal slices increases synaptic strength by increasing functional synapse number, demonstrating a direct role for Trio in dendritic branching and synapse development.","method":"siRNA knockdown in primary neurons, morphometric dendritic analysis, whole-cell electrophysiology in organotypic slices","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function in primary neurons with morphological and electrophysiological readouts, single lab","pmids":["26721934"],"is_preprint":false},{"year":2015,"finding":"Trio and Kalirin play critical and redundant roles in excitatory synapse structure and function. CaMKII phosphorylation of Kalirin is sufficient to enhance synaptic AMPA receptor expression; preventing CaMKII signaling through Kalirin and Trio prevents LTP induction, placing Trio/Kalirin as the elusive CaMKII targets responsible for AMPA receptor upregulation during LTP.","method":"Molecular biology (dominant-negative/constitutively active constructs), electrophysiology (LTP recordings), imaging, biochemical phosphorylation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (electrophysiology + molecular + imaging) demonstrating epistatic relationship and sufficiency of CaMKII-Kalirin/Trio signaling for LTP","pmids":["26858404"],"is_preprint":false},{"year":2015,"finding":"Trio interacts with VE-cadherin at endothelial adherens junctions and locally activates Rac1 during nascent junction formation. The Rac-GEF domain of Trio remodels junctional actin from radial to cortical bundles, promoting linear adherens junction formation and increasing endothelial monolayer resistance.","method":"Co-immunoprecipitation, FRET-based Rac1 biosensor, siRNA knockdown, electrical resistance measurement, actin imaging","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP + FRET biosensor + functional barrier assay, single lab","pmids":["26116572"],"is_preprint":false},{"year":2004,"finding":"Trio interacts with peptidylglycine alpha-amidating monooxygenase (PAM), a secretory granule membrane protein. Cdk5-mediated phosphorylation of Trio (at consensus Cdk5 sites) is required for Trio-dependent Rac activation; roscovitine (Cdk5 inhibitor) inhibits Trio-mediated Rac activation, reorganizes cortical actin, and limits secretory granule approach to the plasma membrane, impairing hormone exocytosis.","method":"Protein interaction (co-IP with PAM), in vitro Cdk5 phosphorylation assay, Rac activation assay, roscovitine pharmacological inhibition, ultrastructural analysis","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay + Rac activation assay + pharmacological perturbation with functional secretion readout, single lab","pmids":["15331630"],"is_preprint":false},{"year":2011,"finding":"Trio mediates HOXC8-dependent CDH11 (cadherin 11)-stimulated breast cancer cell migration by activating Rac1. CDH11 physically interacts with Trio and recruits Trio to the plasma membrane where Trio activates Rac, enabling actin ruffle formation and migration; CDH11 knockdown prevents plasma membrane localization of Trio.","method":"Co-immunoprecipitation, siRNA knockdown, Rac1 activation assay, actin staining, migration assay, immunofluorescence localization","journal":"Genes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP + localization + Rac activation + migration assay, single lab","pmids":["22593800"],"is_preprint":false},{"year":2012,"finding":"Trio acts as the Rac1-activating GEF downstream of the TWEAK-Fn14 signaling axis in glioblastoma cells. Trio depletion inhibits TWEAK-induced Rac1 activation but not Cdc42 activation, and abrogates TWEAK-Fn14-directed glioma cell migration and invasion, while Ect2 depletion blocks both Cdc42 and Rac1 activation.","method":"siRNA knockdown, Rac1/Cdc42 activation assays, migration/invasion assays (Boyden chamber), in vivo RCAS gene transfer model","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective siRNA knockdown with GTPase activation assays and functional migration readouts, single lab","pmids":["22571869"],"is_preprint":false},{"year":2015,"finding":"Hsc70 (heat shock cognate protein 70) dynamically associates with the N-terminal region and Rac1 GEF domain of Trio, supporting Trio-dependent Rac1 activation. ATPase-deficient Hsc70 (D10N) abrogates Trio Rac1 GEF activity and netrin-1-induced Rac1 activation. Hsc70 is required for netrin-1-mediated axon growth and attraction in vitro and supports callosal projections and radial neuronal migration in the embryonic neocortex.","method":"Co-immunoprecipitation, dominant-negative Hsc70 (D10N) expression, Rac1 activation assay, in vitro axon growth assay, in vivo neuronal migration assay","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP + dominant-negative + Rac1 activation + in vivo migration assay, single lab","pmids":["26323693"],"is_preprint":false},{"year":2017,"finding":"RhoG and its exchange factor Trio regulate circular dorsal ruffle (CDR) dynamics, macropinocytosis, receptor internalization, and cell migration. RhoG is activated by Trio downstream of PDGF in a PI3K- and Src-dependent manner. Silencing RhoG decreases CDR number and area independently of Rac1.","method":"siRNA knockdown, GTPase activation assay, CDR live-cell imaging, macropinocytosis assay, pharmacological inhibitors (PI3K, Src)","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown + activation assay + multiple functional readouts, single lab","pmids":["28468978"],"is_preprint":false},{"year":2019,"finding":"TRIO localizes to the Golgi in mouse cerebellar granule neurons and regulates directional membrane trafficking by controlling RAB8- and RAB10-positive vesicle maintenance. The spectrin repeats of Golgi-resident TRIO interact with and activate the RAB GEF RABIN8, thereby activating RAB8 and RAB10. Constitutively active RAB8 or RAB10 partially restores neurite outgrowth in TRIO-deficient neurons.","method":"Co-localization (immunofluorescence), live-cell imaging, FRAP, co-immunoprecipitation, RAB8/RAB10 activation assay, TRIO knockout neuronal rescue experiment","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, live imaging, FRAP, functional rescue) in a single lab","pmids":["31152060"],"is_preprint":false},{"year":2019,"finding":"Trio haploinsufficiency in excitatory neurons causes increased anxiety, impaired social preference, reduced forebrain size, reduced dendritic arborization, increased dendritic spine density, and failure of LTP. PDE4A5 levels are reduced and PKA signaling is increased when TRIO is reduced; elevation of PDE4A5 or attenuation of PKA signaling rescues dendritic spine defects, placing Trio upstream of a PDE4A5-PKA pathway.","method":"Conditional neuron-specific Trio knockout (Cre-lox), behavioral tests, spine morphometry, electrophysiology (LTP), Western blot, pharmacological rescue","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with behavioral, structural, electrophysiological, and biochemical readouts plus pharmacological rescue in one study","pmids":["30840899"],"is_preprint":false},{"year":2021,"finding":"ASD/ID-related Trio mutation D1368V (in GEF1 domain) produces pathological increase in glutamatergic synaptogenesis; Trio N1080I (in spectrin repeat 8) inhibits Trio's interaction with Neuroligin 1 (NLGN1) and prevents Trio D1368V-mediated synaptogenesis. Trio interacts with NLGN1 in the brain, and this interaction is required for NLGN1-mediated NMDA receptor (but not AMPA receptor) synaptic function.","method":"Co-immunoprecipitation from brain, super-resolution spine imaging, whole-cell voltage-clamp electrophysiology in hippocampal slices, molecular biology (mutant constructs)","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP from native brain tissue + mutagenesis + super-resolution imaging + electrophysiology; multiple orthogonal methods","pmids":["34353896"],"is_preprint":false},{"year":2019,"finding":"Synaptic proteomics revealed that Trio interacts with axon guidance and presynaptic complexes (distinct from Kalirin-7 which associates more with synaptic adhesion molecules). These differential interactomes were established by unbiased AP-MS proteomics.","method":"Unbiased affinity purification mass spectrometry (AP-MS) proteomics","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — unbiased proteomics identifying distinct interactomes, single lab","pmids":["31801062"],"is_preprint":false},{"year":2020,"finding":"The GEF1 domain of Trio and activation of Rac1 and RhoG in the cell periphery are required for VEGF-signaling-dependent enlargement of arterial endothelial cells, driving large-caliber artery formation in zebrafish and cell models. This involves F-actin remodeling, myosin-based tension at junctions, and focal adhesions. Vegf signaling strength is titrated by soluble Flt1 to control Trio activity.","method":"Zebrafish embryo genetics (morpholino/mutant), GEF1-domain-specific Trio constructs, endothelial cell models, actin imaging, focal adhesion analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo zebrafish + cell model with domain-specific constructs, single lab","pmids":["33087700"],"is_preprint":false},{"year":2021,"finding":"Trio conditional knockout in excitatory cortical/hippocampal neurons causes aberrant polarity and halted migration of late-born pyramidal neurons. The Trio N-terminal SH3 domain interacts with Myosin X, mediating adherence of migrating neurons to radial glial fibers by regulating N-cadherin membrane localization. Independent or synergistic overexpression of RAC1 and RHOA produces different phenotypic recoveries, demonstrating distinct roles of GEF1 (RAC1) and GEF2 (RHOA) domains in radial migration.","method":"Conditional knockout, in utero electroporation, immunofluorescence, Co-IP (SH3-Myosin X), N-cadherin membrane localization assay, rescue with constitutively active RAC1/RHOA","journal":"Neuroscience bulletin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO + Co-IP + domain-specific rescue, single lab","pmids":["34914033"],"is_preprint":false},{"year":2022,"finding":"Spectrin repeats (SRs) 6-9 of Trio interact intramolecularly with the GEF1 domain to autoinhibit its catalytic activity both in vitro and in cells. NDD-associated variants in SR8 and GEF1 domain relieve this autoinhibitory constraint. Chemical cross-linking and bio-layer interferometry indicate SRs primarily contact the pleckstrin homology region of GEF1, reducing GEF1 binding to Rac1.","method":"In vitro GEF activity assay, cell-based Rac1 activation assay, chemical cross-linking mass spectrometry, bio-layer interferometry, NDD variant mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of autoinhibition + structural mapping by cross-linking MS + bio-layer interferometry + cell-based validation; multiple Tier 1-2 methods in single study","pmids":["35963430"],"is_preprint":false},{"year":2012,"finding":"TRIO is amplified and overexpressed in urinary bladder cancer and soft tissue sarcomas; TRIO amplification strongly associates with invasive tumor phenotype, high tumor grade, and rapid cell proliferation (Ki67). However, these are correlative findings — no direct mechanistic experiment was performed in this paper.","method":"FISH on tissue microarray, RNA in situ hybridization","journal":"The American journal of pathology","confidence":"Low","confidence_rationale":"Tier 4 / Weak — purely correlative genomic/expression analysis with no direct mechanistic experiment on Trio protein function","pmids":["15215162"],"is_preprint":false},{"year":2020,"finding":"ALKBH5, an m6A RNA demethylase, is downregulated during myocardial ischemia/reperfusion injury (MIRI). MeRIP-seq and RNA-seq in ALKBH5-overexpressed HL-1 cells identified Trio mRNA as a target whose m6A modification level is increased when ALKBH5 is lost, leading to decreased Trio expression. Overexpression of ALKBH5 is protective against MIRI-related cell injury and apoptosis.","method":"MeRIP-seq, RNA-seq, MeRIP-qPCR, siRNA/overexpression, cell viability/apoptosis assays","journal":"Annals of translational medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — methylation sequencing identifies Trio mRNA as m6A target but functional link between Trio m6A modification and MIRI is inferred rather than directly demonstrated with Trio-specific rescue","pmids":["35530959"],"is_preprint":false},{"year":2020,"finding":"Trio interacts with ANKRD26 protein (identified by yeast two-hybrid and immunoprecipitation). Selective knockdown of Trio increases adipogenesis in 3T3-L1 cells, establishing Trio as a regulator of adipogenesis.","method":"Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, adipogenesis assay","journal":"PloS one","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast two-hybrid + single Co-IP + knockdown phenotype; single lab, limited mechanistic follow-up","pmids":["22666460"],"is_preprint":false},{"year":2018,"finding":"Trio is expressed in glomerular podocytes and activates basal Rac1 activity. Reduced Trio expression in cultured human podocytes decreases basal Rac1 activity, cell size, laminin attachment, and motility. TGFβ1 increases Rac1 activity in control cells but decreases it in Trio-knockdown cells (attributed to simultaneous CdGAP activation).","method":"siRNA knockdown, Rac1 activation assay, cell size/adhesion/motility assays, RNA-seq expression profiling","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — knockdown + Rac1 activation assay in cultured cells, single lab, limited mechanistic depth","pmids":["29415466"],"is_preprint":false},{"year":2015,"finding":"Trio gene deletion in EMX1-Cre mice (brain cortex and hippocampus) results in smaller brains, abnormal hippocampal structure, and disordered granule cells in DG and CA regions. EMX1-Trio(-/-) mice show impaired hippocampal-dependent spatial learning, establishing Trio's role in adult hippocampal-dependent learning.","method":"Conditional knockout (EMX1-Cre), brain morphology analysis, behavioral tests (spatial learning/Morris water maze)","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined hippocampal phenotype and behavioral readout, single lab","pmids":["25727174"],"is_preprint":false},{"year":2020,"finding":"Trio is required for Xenopus cranial neural crest cell migration and cartilage formation. Trio cell-autonomously controls protrusion formation; Trio GEF2 domain is sufficient to rescue protrusion and migration defects. The Trio GEF2 domain interacts with the DEP/C-terminus of Dishevelled (DVL), and DVL rescues Rac1 activity and protrusion formation in Trio morphant embryos, defining a Trio-DVL-Rac1 pathway in neural crest migration.","method":"Morpholino knockdown in Xenopus, rescue with domain-specific constructs, Co-IP (Trio GEF2 - DVL), Rac1 activation assay, live-cell imaging of protrusions","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — morpholino knockdown + domain-specific rescue + Co-IP + Rac1 activation; multiple orthogonal methods, single lab","pmids":["32366678"],"is_preprint":false}],"current_model":"TRIO is a multidomain Rho guanine nucleotide exchange factor (RhoGEF) containing two catalytic GEF domains (GEF1 activates Rac1/RhoG; GEF2 activates RhoA), a serine/threonine kinase domain, spectrin repeats, SH3 domains, and other scaffolding domains; the spectrin repeats 6-9 autoinhibit GEF1 activity by contacting its PH region, and NDD-associated mutations relieve this constraint. Trio is activated downstream of cell-surface receptors including the netrin receptor DCC (mediating Rac1-dependent axon guidance), Gαq-coupled receptors (activating RhoA together with PLCβ), VEGFR (driving arterial remodeling), and the NOTCH-DAB1-ABL axis (via ABL-mediated phosphorylation at Y2681 to activate RhoA in cancer invasion). Trio interacts physically with FAK, VE-cadherin, Neuroligin-1, Hsc70, Myosin X, RABIN8 (activating RAB8/RAB10 from the Golgi), and ANKRD26. In neurons, CaMKII phosphorylates the Trio paralog Kalirin (and redundantly Trio) to drive AMPA receptor upregulation and LTP; Trio also controls radial migration, dendritic branching, synapse formation, and spatial learning via Rac1 and RhoA, while at non-neuronal sites it regulates endothelial barrier integrity, apical constriction, invadopodia disassembly, and exocytosis through context-specific GTPase activation."},"narrative":{"mechanistic_narrative":"TRIO is a multidomain Rho-family guanine nucleotide exchange factor that couples cell-surface receptor signaling to actin cytoskeletal remodeling, governing axon guidance, neuronal migration, synapse formation, and morphogenetic cell movements [PMID:11050238, PMID:18212043]. Its two catalytic GEF domains are functionally specialized: the N-terminal GEF1 domain activates Rac1 (and RhoG) to drive membrane ruffling, spreading, and migration, while the C-terminal GEF2 domain activates RhoA, and these activities can be experimentally separated by domain-specific constructs and the GEF1-selective inhibitor ITX3 [PMID:10341202, PMID:19549603, PMID:34914033]. GEF1 catalytic output is held in check by an intramolecular autoinhibitory contact in which spectrin repeats 6-9 engage the GEF1 pleckstrin-homology region to reduce Rac1 binding; neurodevelopmental-disorder variants in SR8 and GEF1 relieve this constraint, and the GEF1 mutation D1368V drives pathological glutamatergic synaptogenesis [PMID:35963430, PMID:34353896]. TRIO is deployed downstream of multiple receptors through distinct adaptors: it binds the netrin receptor DCC/Frazzled to mediate Rac1-dependent commissural axon guidance and neurite outgrowth [PMID:18212043, PMID:15790972], acts as a major Gαq effector that synergizes with PLCβ to activate RhoA [PMID:17942708], and is recruited by VE-cadherin, CDH11, the TWEAK-Fn14 axis, and VEGF/Flt1 signaling to control endothelial junctions, tumor cell migration, and arterial caliber via local Rac1/RhoG activation [PMID:26116572, PMID:22593800, PMID:22571869, PMID:33087700]. TRIO function is tuned by phosphorylation—by FAK at Y2737, by Cdk5, and by ABL at Y2681 downstream of a NOTCH-DAB1-ABL cascade that promotes RhoA-driven cancer invasion [PMID:12551902, PMID:15331630, PMID:25432929]. In the nervous system TRIO and its paralog Kalirin act redundantly as the CaMKII targets required for synaptic AMPA receptor upregulation during LTP, and TRIO controls dendritic branching, synapse number, radial migration, and spatial learning, with conditional loss producing reduced forebrain size, spine and LTP deficits, and a PDE4A5-PKA signaling imbalance [PMID:26858404, PMID:26721934, PMID:30840899, PMID:25727174]. TRIO additionally scaffolds membrane trafficking through Hsc70 and a Golgi-localized spectrin-repeat interaction with RABIN8 that activates RAB8/RAB10, and engages Myosin X via its SH3 domain to regulate N-cadherin-dependent adhesion during migration [PMID:26323693, PMID:31152060, PMID:34914033]. Beyond neurons, GEF1-driven Rac1 activation directs invadopodia disassembly and apical constriction during epithelial morphogenesis [PMID:24859002, PMID:22031541].","teleology":[{"year":1999,"claim":"Established that Trio's two GEF domains are functionally distinct effectors of cytoskeletal change, with GEF1 driving ruffling/migration/transformation and GEF2 a separate lamellar phenotype.","evidence":"Stable expression of individual GEF domains in NIH 3T3/COS cells with actin staining, haptotaxis, and soft-agar growth assays","pmids":["10341202"],"confidence":"Medium","gaps":["No in vitro biochemical reconstitution of GEF activity","GTPase specificity of each domain not directly defined here"]},{"year":2000,"claim":"Defined Trio as essential in vivo, linking it to skeletal muscle formation and neural tissue organization through a loss-of-function embryonic phenotype.","evidence":"Constitutive trio-/- mouse knockout with histology across muscle and brain","pmids":["11050238"],"confidence":"High","gaps":["Did not resolve which GEF domain or GTPase mediates each tissue defect","Cell-autonomous vs non-autonomous mechanism unaddressed"]},{"year":2003,"claim":"Showed Trio is integrated with focal adhesion signaling, binding and reciprocally activating FAK and being phosphorylated at Y2737.","evidence":"Reciprocal Co-IP, immunofluorescence co-localization, in vitro kinase assay and phosphopeptide mapping","pmids":["12551902"],"confidence":"Medium","gaps":["Functional consequence of Y2737 phosphorylation for GEF activity not established","Single-lab in vitro kinase data"]},{"year":2004,"claim":"Connected Trio to regulated exocytosis, showing Cdk5 phosphorylation gates Trio-dependent Rac activation and secretory granule trafficking.","evidence":"Co-IP with PAM, in vitro Cdk5 kinase assay, Rac activation assay, roscovitine inhibition with ultrastructural readout","pmids":["15331630"],"confidence":"Medium","gaps":["Cdk5 phosphosites not mapped to functional residues","Pharmacological Cdk5 inhibition not isoform-specific"]},{"year":2005,"claim":"Placed Trio genetically downstream of Netrin/Frazzled axon guidance and as an ABL phosphorylation target in Drosophila.","evidence":"GST-pulldown, Co-IP, genetic epistasis across allele combinations, S2 cell phosphorylation","pmids":["15790972"],"confidence":"High","gaps":["Which GTPase mediates Frazzled output not resolved in this study","ABL phosphosite not mapped here"]},{"year":2007,"claim":"Identified the Trio/UNC-73 RhoGEF domain as a major Gαq effector activating RhoA in synergy with PLCβ, defining a parallel Gq output.","evidence":"Forward genetic suppressor screen, double-mutant epistasis, cell-based and biochemical Rho activation assays, Co-IP in C. elegans","pmids":["17942708"],"confidence":"High","gaps":["Direct mammalian Gαq-Trio biochemistry not shown here","Structural basis of Gαq-RhoGEF synergy unresolved"]},{"year":2008,"claim":"Demonstrated Trio physically links the netrin receptor DCC to Rac1 activation required for commissural axon guidance in mammals.","evidence":"Co-IP from embryonic brain, Trio-/- neurite/explant guidance assays, in vivo axon tract analysis","pmids":["18212043"],"confidence":"High","gaps":["Mechanism of DCC-induced Trio activation not defined","Role of GEF2/RhoA in guidance unaddressed"]},{"year":2009,"claim":"Provided a selective chemical tool (ITX3) confirming a discrete Trio/RhoG/Rac1 pathway controlling neurite outgrowth and myotube differentiation.","evidence":"Inhibitor screen against TrioN/GEF1, Rac1 activation, ruffling, neurite and myotube differentiation assays","pmids":["19549603"],"confidence":"Medium","gaps":["Off-target profile beyond tested GEFs not exhaustive","In vivo efficacy not tested"]},{"year":2011,"claim":"Established Trio as the RhoA-GEF executing Shroom3-driven apical constriction during epithelial invagination.","evidence":"siRNA, dominant-negative/constitutively active RhoA, Rock inhibition, in vivo lens pit assay","pmids":["22031541"],"confidence":"Medium","gaps":["How Shroom3 recruits/activates Trio not defined","Single-lab knockdown evidence"]},{"year":2012,"claim":"Extended Trio's Rac1-GEF role to cancer cell migration via CDH11- and TWEAK-Fn14-dependent recruitment and ANKRD26 binding in adipogenesis.","evidence":"Co-IP, yeast two-hybrid, siRNA, Rac1/Cdc42 activation, migration/invasion and adipogenesis assays across studies","pmids":["22593800","22571869","22666460"],"confidence":"Medium","gaps":["ANKRD26 interaction limited to Y2H plus single Co-IP","Receptor-to-Trio activation mechanisms not fully reconstituted"]},{"year":2014,"claim":"Defined opposing roles for Trio-Rac1 in actin structures—driving invadopodia disassembly—and identified ABL phosphorylation of Y2681 downstream of NOTCH-DAB1 as a switch for RhoA-driven invasion.","evidence":"Rac1 FRET biosensor and photoactivation; phospho-specific antibody, Y2681F mutant rescue, ABL inhibition, invasion assays","pmids":["24859002","25432929"],"confidence":"High","gaps":["Structural effect of Y2681 phosphorylation on GEF2 unknown","Interplay of GEF1 and GEF2 outputs in the same cell not reconciled"]},{"year":2015,"claim":"Identified Trio (redundant with Kalirin) as the long-sought CaMKII target driving AMPA receptor upregulation during LTP, while also controlling dendritic branching, synapse number, and spatial learning.","evidence":"LTP electrophysiology with dominant-negative/CA constructs, siRNA in primary neurons, organotypic slice physiology, conditional EMX1-Cre KO behavior","pmids":["26858404","26721934","25727174"],"confidence":"High","gaps":["Direct CaMKII phosphosite on Trio not mapped here","GTPase identity downstream of CaMKII-Trio for AMPAR insertion not resolved"]},{"year":2015,"claim":"Showed Trio engages additional partners—VE-cadherin at endothelial junctions and the chaperone Hsc70—to spatially control Rac1 activation in junction formation, axon growth, and neuronal migration.","evidence":"Co-IP, Rac1 FRET biosensor, ATPase-dead Hsc70 D10N, barrier resistance, axon growth and in vivo migration assays","pmids":["26116572","26323693"],"confidence":"Medium","gaps":["How Hsc70 ATPase cycle gates GEF1 catalysis mechanistically unclear","Single-lab Co-IP evidence for each interaction"]},{"year":2017,"claim":"Established Trio-RhoG signaling downstream of PDGF/PI3K/Src controls dorsal ruffle dynamics, macropinocytosis, and receptor internalization independently of Rac1.","evidence":"siRNA, GTPase activation, CDR/macropinocytosis live imaging, PI3K/Src inhibitors","pmids":["28468978"],"confidence":"Medium","gaps":["Direct biochemical link from PDGFR to Trio not shown","RhoG vs Rac1 separation incomplete"]},{"year":2019,"claim":"Revealed Trio scaffolding of membrane trafficking via Golgi RABIN8-RAB8/RAB10 activation and distinct synaptic interactomes, and clarified its haploinsufficiency phenotype via a PDE4A5-PKA axis.","evidence":"Co-IP, FRAP, RAB8/RAB10 activation and rescue, AP-MS proteomics, conditional KO with behavior, LTP, spine morphometry and pharmacological rescue","pmids":["31152060","31801062","30840899"],"confidence":"High","gaps":["How GEF activity and RABIN8 scaffolding are coordinated unclear","Mechanism linking Trio to PDE4A5 levels not defined"]},{"year":2020,"claim":"Defined GEF-domain-specialized roles in tissue morphogenesis: GEF1/Rac1-RhoG in VEGF-driven arterial caliber, and GEF2-RhoA via Dishevelled in neural crest migration.","evidence":"Zebrafish and Xenopus genetics, domain-specific rescue, Co-IP (GEF2-DVL), Rac1 activation, actin/protrusion imaging","pmids":["33087700","32366678"],"confidence":"Medium","gaps":["Receptor-proximal activation of each GEF domain not reconstituted","Cross-talk between GEF1 and GEF2 in same tissue unresolved"]},{"year":2021,"claim":"Mapped a spectrin-repeat/Neuroligin-1 interaction controlling NMDA-receptor synaptic function and showed GEF1 variant D1368V drives pathological synaptogenesis blocked by an SR8 variant disrupting NLGN1 binding.","evidence":"Brain Co-IP, super-resolution spine imaging, voltage-clamp electrophysiology, mutant constructs","pmids":["34353896"],"confidence":"High","gaps":["How NLGN1 binding regulates GEF1 catalytic output mechanistically unclear","Selectivity for NMDA over AMPA function not fully explained"]},{"year":2022,"claim":"Resolved the autoinhibitory architecture: spectrin repeats 6-9 contact the GEF1 PH region to suppress Rac1 binding, and NDD variants relieve this constraint—providing a unifying mechanism for disease mutations.","evidence":"In vitro and cell-based GEF assays, cross-linking MS, bio-layer interferometry, NDD variant mutagenesis","pmids":["35963430"],"confidence":"High","gaps":["High-resolution structure of the autoinhibited state lacking","How upstream receptors physically relieve autoinhibition unknown"]},{"year":null,"claim":"How distinct upstream receptors selectively relieve GEF1 autoinhibition and choose between GEF1/Rac1 and GEF2/RhoA outputs within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of receptor-triggered de-repression","Coordination of GEF1 vs GEF2 activity in shared contexts undefined","Direct in vivo requirement of each phosphosite (Y2737, Y2681, Cdk5 sites) not dissected together"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,24]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,4]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[18,23]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,12,14]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[18]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[1,8,12]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,4,9]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,2,22,30]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[11,19,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,15]}],"complexes":[],"partners":["DCC","FAK","VE-CADHERIN","NLGN1","HSC70","RABIN8","MYO10","DVL"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O75962","full_name":"Triple functional domain protein","aliases":["PTPRF-interacting protein"],"length_aa":3097,"mass_kda":346.9,"function":"Guanine nucleotide exchange factor (GEF) for RHOA and RAC1 GTPases (PubMed:22155786, PubMed:27418539, PubMed:8643598). Involved in coordinating actin remodeling, which is necessary for cell migration and growth (PubMed:10341202, PubMed:22155786). Plays a key role in the regulation of neurite outgrowth and lamellipodia formation (PubMed:32109419). In developing hippocampal neurons, limits dendrite formation, without affecting the establishment of axon polarity. Once dendrites are formed, involved in the control of synaptic function by regulating the endocytosis of AMPA-selective glutamate receptors (AMPARs) at CA1 excitatory synapses (By similarity). May act as a regulator of adipogenesis (By similarity)","subcellular_location":"Cytoplasm; Cell projection","url":"https://www.uniprot.org/uniprotkb/O75962/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TRIO","classification":"Not Classified","n_dependent_lines":72,"n_total_lines":1208,"dependency_fraction":0.059602649006622516},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TRIO","total_profiled":1310},"omim":[{"mim_id":"621511","title":"LETHAL CONGENITAL CONTRACTURE SYNDROME 12; LCCS12","url":"https://www.omim.org/entry/621511"},{"mim_id":"621500","title":"EPILEPSY, IDIOPATHIC GENERALIZED 20; EIG20","url":"https://www.omim.org/entry/621500"},{"mim_id":"621456","title":"NEURODEVELOPMENTAL DISORDER WITH SPEECH DELAY, MOVEMENT ABNORMALITIES, AND SEIZURES; NEDSMS","url":"https://www.omim.org/entry/621456"},{"mim_id":"621377","title":"HAREL-TORA NEURODEVELOPMENTAL SYNDROME; HATONS","url":"https://www.omim.org/entry/621377"},{"mim_id":"621372","title":"NEURODEVELOPMENTAL DISORDER WITH SPEECH DELAY AND BEHAVIORAL ABNORMALITIES; NEDSBH","url":"https://www.omim.org/entry/621372"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TRIO"},"hgnc":{"alias_symbol":["ARHGEF23"],"prev_symbol":[]},"alphafold":{"accession":"O75962","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75962","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75962-5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75962-5-F1-predicted_aligned_error_v6.png","plddt_mean":67.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRIO","jax_strain_url":"https://www.jax.org/strain/search?query=TRIO"},"sequence":{"accession":"O75962","fasta_url":"https://rest.uniprot.org/uniprotkb/O75962.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75962/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75962"}},"corpus_meta":[{"pmid":"25524798","id":"PMC_25524798","title":"The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.","date":"2014","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25524798","citation_count":1536,"is_preprint":false},{"pmid":"29539642","id":"PMC_29539642","title":"A TRP channel trio mediates acute noxious heat sensing.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29539642","citation_count":365,"is_preprint":false},{"pmid":"34010611","id":"PMC_34010611","title":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.","date":"2021","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34010611","citation_count":331,"is_preprint":false},{"pmid":"21652514","id":"PMC_21652514","title":"A trio of microRNAs that control Toll-like receptor signalling.","date":"2011","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21652514","citation_count":252,"is_preprint":false},{"pmid":"18533280","id":"PMC_18533280","title":"CXCR7, CXCR4 and CXCL12: an eccentric trio?","date":"2008","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/18533280","citation_count":199,"is_preprint":false},{"pmid":"18462747","id":"PMC_18462747","title":"The PPAR trio: regulators of myocardial energy metabolism in health and disease.","date":"2008","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/18462747","citation_count":195,"is_preprint":false},{"pmid":"33011613","id":"PMC_33011613","title":"Intestinal barrier damage, systemic inflammatory response syndrome, and acute lung injury: A troublesome trio for acute pancreatitis.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/33011613","citation_count":183,"is_preprint":false},{"pmid":"22989616","id":"PMC_22989616","title":"Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.","date":"2012","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22989616","citation_count":165,"is_preprint":false},{"pmid":"19444308","id":"PMC_19444308","title":"A molecular trio in relapse and remission in multiple sclerosis.","date":"2009","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19444308","citation_count":159,"is_preprint":false},{"pmid":"11050238","id":"PMC_11050238","title":"Skeletal muscle deformity and neuronal disorder in Trio exchange factor-deficient mouse embryos.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11050238","citation_count":146,"is_preprint":false},{"pmid":"24859002","id":"PMC_24859002","title":"A Trio-Rac1-Pak1 signalling axis drives invadopodia disassembly.","date":"2014","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24859002","citation_count":136,"is_preprint":false},{"pmid":"18212043","id":"PMC_18212043","title":"Trio mediates netrin-1-induced Rac1 activation in axon outgrowth and guidance.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18212043","citation_count":118,"is_preprint":false},{"pmid":"32415068","id":"PMC_32415068","title":"The native ORAI channel trio underlies the diversity of Ca2+ signaling events.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32415068","citation_count":115,"is_preprint":false},{"pmid":"22117646","id":"PMC_22117646","title":"Insights into mitochondrial dysfunction: aging, amyloid-β, and tau-A deleterious trio.","date":"2012","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22117646","citation_count":109,"is_preprint":false},{"pmid":"22031541","id":"PMC_22031541","title":"A Trio-RhoA-Shroom3 pathway is required for apical constriction and epithelial invagination.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22031541","citation_count":99,"is_preprint":false},{"pmid":"15790972","id":"PMC_15790972","title":"The Abelson tyrosine kinase, the Trio GEF and Enabled interact with the Netrin receptor Frazzled in Drosophila.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15790972","citation_count":98,"is_preprint":false},{"pmid":"17396138","id":"PMC_17396138","title":"S100A1 and S100B, transcriptional targets of SOX trio, inhibit terminal differentiation of chondrocytes.","date":"2007","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/17396138","citation_count":94,"is_preprint":false},{"pmid":"25432929","id":"PMC_25432929","title":"Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO.","date":"2014","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/25432929","citation_count":89,"is_preprint":false},{"pmid":"26721934","id":"PMC_26721934","title":"TRIO loss of function is associated with mild intellectual disability and affects dendritic branching and synapse function.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26721934","citation_count":88,"is_preprint":false},{"pmid":"23279723","id":"PMC_23279723","title":"An infernal trio: the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology.","date":"2012","source":"Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft","url":"https://pubmed.ncbi.nlm.nih.gov/23279723","citation_count":87,"is_preprint":false},{"pmid":"19549603","id":"PMC_19549603","title":"A cell active chemical GEF inhibitor selectively targets the Trio/RhoG/Rac1 signaling pathway.","date":"2009","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/19549603","citation_count":87,"is_preprint":false},{"pmid":"35794475","id":"PMC_35794475","title":"A receptor-channel trio conducts Ca2+ signalling for pollen tube reception.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35794475","citation_count":86,"is_preprint":false},{"pmid":"26858404","id":"PMC_26858404","title":"Kalirin and Trio proteins serve critical roles in excitatory synaptic transmission and LTP.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26858404","citation_count":85,"is_preprint":false},{"pmid":"24987837","id":"PMC_24987837","title":"Function and regulation of the Rho guanine nucleotide exchange factor Trio.","date":"2014","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/24987837","citation_count":78,"is_preprint":false},{"pmid":"22571869","id":"PMC_22571869","title":"Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells.","date":"2012","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/22571869","citation_count":75,"is_preprint":false},{"pmid":"17942708","id":"PMC_17942708","title":"Trio's Rho-specific GEF domain is the missing Galpha q effector in C. elegans.","date":"2007","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/17942708","citation_count":72,"is_preprint":false},{"pmid":"11493634","id":"PMC_11493634","title":"The Trio family of guanine-nucleotide-exchange factors: regulators of axon guidance.","date":"2001","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/11493634","citation_count":70,"is_preprint":false},{"pmid":"29892818","id":"PMC_29892818","title":"The Deiodinase Trio and Thyroid Hormone Signaling.","date":"2018","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/29892818","citation_count":67,"is_preprint":false},{"pmid":"25544252","id":"PMC_25544252","title":"Quantifiler® Trio Kit and forensic samples management: a matter of degradation.","date":"2014","source":"Forensic science international. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25544252","citation_count":64,"is_preprint":false},{"pmid":"10341202","id":"PMC_10341202","title":"Trio amino-terminal guanine nucleotide exchange factor domain expression promotes actin cytoskeleton reorganization, cell migration and anchorage-independent cell growth.","date":"1999","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/10341202","citation_count":63,"is_preprint":false},{"pmid":"26116572","id":"PMC_26116572","title":"A local VE-cadherin and Trio-based signaling complex stabilizes endothelial junctions through Rac1.","date":"2015","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/26116572","citation_count":62,"is_preprint":false},{"pmid":"12551902","id":"PMC_12551902","title":"Signaling between focal adhesion kinase and trio.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12551902","citation_count":60,"is_preprint":false},{"pmid":"27281207","id":"PMC_27281207","title":"The bacterial DnaA-trio replication origin element specifies single-stranded DNA initiator binding.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/27281207","citation_count":59,"is_preprint":false},{"pmid":"15215162","id":"PMC_15215162","title":"TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15215162","citation_count":55,"is_preprint":false},{"pmid":"33203854","id":"PMC_33203854","title":"Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33203854","citation_count":54,"is_preprint":false},{"pmid":"23076143","id":"PMC_23076143","title":"The many faces of the guanine-nucleotide exchange factor trio.","date":"2012","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/23076143","citation_count":51,"is_preprint":false},{"pmid":"15715966","id":"PMC_15715966","title":"Multiple novel isoforms of Trio are expressed in the developing rat brain.","date":"2005","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/15715966","citation_count":51,"is_preprint":false},{"pmid":"15331630","id":"PMC_15331630","title":"Cdk5 and Trio modulate endocrine cell exocytosis.","date":"2004","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15331630","citation_count":46,"is_preprint":false},{"pmid":"34958143","id":"PMC_34958143","title":"Trio exome sequencing is highly relevant in prenatal diagnostics.","date":"2021","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/34958143","citation_count":44,"is_preprint":false},{"pmid":"16752383","id":"PMC_16752383","title":"Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas.","date":"2006","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16752383","citation_count":44,"is_preprint":false},{"pmid":"30840899","id":"PMC_30840899","title":"Trio Haploinsufficiency Causes Neurodevelopmental Disease-Associated Deficits.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30840899","citation_count":43,"is_preprint":false},{"pmid":"19784764","id":"PMC_19784764","title":"Mitochondria, cholesterol and amyloid beta peptide: a dangerous trio in Alzheimer disease.","date":"2009","source":"Journal of bioenergetics and biomembranes","url":"https://pubmed.ncbi.nlm.nih.gov/19784764","citation_count":43,"is_preprint":false},{"pmid":"19273385","id":"PMC_19273385","title":"Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio.","date":"2009","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/19273385","citation_count":42,"is_preprint":false},{"pmid":"32329217","id":"PMC_32329217","title":"Activation of the SOX-5, SOX-6, and SOX-9 Trio of Transcription Factors Using a Gene-Activated Scaffold Stimulates Mesenchymal Stromal Cell Chondrogenesis and Inhibits Endochondral Ossification.","date":"2020","source":"Advanced healthcare materials","url":"https://pubmed.ncbi.nlm.nih.gov/32329217","citation_count":42,"is_preprint":false},{"pmid":"22564423","id":"PMC_22564423","title":"Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.","date":"2012","source":"Archives of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/22564423","citation_count":40,"is_preprint":false},{"pmid":"24854956","id":"PMC_24854956","title":"Osteochondral tissue regeneration through polymeric delivery of DNA encoding for the SOX trio and RUNX2.","date":"2014","source":"Acta biomaterialia","url":"https://pubmed.ncbi.nlm.nih.gov/24854956","citation_count":40,"is_preprint":false},{"pmid":"27528700","id":"PMC_27528700","title":"Recurrent TRIO Fusion in Nontranslocation-Related Sarcomas.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27528700","citation_count":39,"is_preprint":false},{"pmid":"35948068","id":"PMC_35948068","title":"HIF1, HSF1, and NRF2: Oxidant-Responsive Trio Raising Cellular Defenses and Engaging Immune System.","date":"2022","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35948068","citation_count":38,"is_preprint":false},{"pmid":"32933663","id":"PMC_32933663","title":"Hyaluronic acid wreathed, trio-stimuli receptive and on-demand triggerable nanoconstruct for anchored combinatorial cancer therapy.","date":"2020","source":"Carbohydrate polymers","url":"https://pubmed.ncbi.nlm.nih.gov/32933663","citation_count":38,"is_preprint":false},{"pmid":"36055233","id":"PMC_36055233","title":"Nonparametric single-cell multiomic characterization of trio relationships between transcription factors, target genes, and cis-regulatory regions.","date":"2022","source":"Cell systems","url":"https://pubmed.ncbi.nlm.nih.gov/36055233","citation_count":37,"is_preprint":false},{"pmid":"25727174","id":"PMC_25727174","title":"Trio gene is required for mouse learning ability.","date":"2015","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/25727174","citation_count":37,"is_preprint":false},{"pmid":"8179856","id":"PMC_8179856","title":"Cytosolic Ca2+, Na+/H+ antiport, protein kinase C trio in essential hypertension.","date":"1994","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/8179856","citation_count":36,"is_preprint":false},{"pmid":"22593800","id":"PMC_22593800","title":"HOXC8-Dependent Cadherin 11 Expression Facilitates Breast Cancer Cell Migration through Trio and Rac.","date":"2011","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22593800","citation_count":36,"is_preprint":false},{"pmid":"33087700","id":"PMC_33087700","title":"The GEF Trio controls endothelial cell size and arterial remodeling downstream of Vegf signaling in both zebrafish and cell models.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33087700","citation_count":36,"is_preprint":false},{"pmid":"32630530","id":"PMC_32630530","title":"Angiotensin II, Hypercholesterolemia, and Vascular Smooth Muscle Cells: A Perfect Trio for Vascular Pathology.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32630530","citation_count":35,"is_preprint":false},{"pmid":"21728837","id":"PMC_21728837","title":"SOX trio decrease in the articular cartilage with the advancement of osteoarthritis.","date":"2011","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/21728837","citation_count":34,"is_preprint":false},{"pmid":"33387132","id":"PMC_33387132","title":"Direct and Indirect Effects of Maternal, Paternal, and Offspring Genotypes: Trio-GCTA.","date":"2021","source":"Behavior genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33387132","citation_count":33,"is_preprint":false},{"pmid":"28468978","id":"PMC_28468978","title":"Regulation of circular dorsal ruffles, macropinocytosis, and cell migration by RhoG and its exchange factor, Trio.","date":"2017","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/28468978","citation_count":33,"is_preprint":false},{"pmid":"29154454","id":"PMC_29154454","title":"Identification of de novo germline mutations and causal genes for sporadic diseases using trio-based whole-exome/genome sequencing.","date":"2017","source":"Biological reviews of the Cambridge Philosophical Society","url":"https://pubmed.ncbi.nlm.nih.gov/29154454","citation_count":32,"is_preprint":false},{"pmid":"34353896","id":"PMC_34353896","title":"Autism Spectrum Disorder/Intellectual Disability-Associated Mutations in Trio Disrupt Neuroligin 1-Mediated Synaptogenesis.","date":"2021","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34353896","citation_count":31,"is_preprint":false},{"pmid":"31680349","id":"PMC_31680349","title":"Trio-whole-exome sequencing and preimplantation genetic diagnosis for unexplained recurrent fetal malformations.","date":"2019","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/31680349","citation_count":31,"is_preprint":false},{"pmid":"36075896","id":"PMC_36075896","title":"Circ-TRIO promotes TNBC progression by regulating the miR-432-5p/CCDC58 axis.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36075896","citation_count":30,"is_preprint":false},{"pmid":"15649349","id":"PMC_15649349","title":"Engulfment: ingestion and migration with Rac, Rho and TRIO.","date":"2005","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/15649349","citation_count":30,"is_preprint":false},{"pmid":"22666460","id":"PMC_22666460","title":"ANKRD26 and its interacting partners TRIO, GPS2, HMMR and DIPA regulate adipogenesis in 3T3-L1 cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22666460","citation_count":30,"is_preprint":false},{"pmid":"33568469","id":"PMC_33568469","title":"Trio family proteins as regulators of cell migration and morphogenesis in development and disease - mechanisms and cellular contexts.","date":"2021","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/33568469","citation_count":29,"is_preprint":false},{"pmid":"34791078","id":"PMC_34791078","title":"High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases.","date":"2022","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34791078","citation_count":29,"is_preprint":false},{"pmid":"21251990","id":"PMC_21251990","title":"Electroporation-mediated gene transfer of SOX trio to enhance chondrogenesis in adipose stem cells.","date":"2011","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/21251990","citation_count":29,"is_preprint":false},{"pmid":"26323693","id":"PMC_26323693","title":"Hsc70 chaperone activity underlies Trio GEF function in axon growth and guidance induced by netrin-1.","date":"2015","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26323693","citation_count":27,"is_preprint":false},{"pmid":"31801062","id":"PMC_31801062","title":"Synaptic Kalirin-7 and Trio Interactomes Reveal a GEF Protein-Dependent Neuroligin-1 Mechanism of Action.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31801062","citation_count":26,"is_preprint":false},{"pmid":"19635737","id":"PMC_19635737","title":"Combining case-control and case-trio data from the same population in genetic association analyses: overview of approaches and illustration with a candidate gene study.","date":"2009","source":"American journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/19635737","citation_count":26,"is_preprint":false},{"pmid":"15669055","id":"PMC_15669055","title":"Expression of Trio, a member of the Dbl family of Rho GEFs in the developing rat brain.","date":"2005","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15669055","citation_count":26,"is_preprint":false},{"pmid":"30952205","id":"PMC_30952205","title":"Identification of Hürthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithms.","date":"2019","source":"BMC systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/30952205","citation_count":25,"is_preprint":false},{"pmid":"34321325","id":"PMC_34321325","title":"Diagnostic yield of chromosomal microarray and trio whole exome sequencing in cryptogenic cerebral palsy.","date":"2021","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34321325","citation_count":24,"is_preprint":false},{"pmid":"30518673","id":"PMC_30518673","title":"A Methyltransferase Trio Essential for Phosphatidylcholine Biosynthesis and Growth.","date":"2018","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30518673","citation_count":23,"is_preprint":false},{"pmid":"31152060","id":"PMC_31152060","title":"Golgi-resident TRIO regulates membrane trafficking during neurite outgrowth.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31152060","citation_count":23,"is_preprint":false},{"pmid":"21825870","id":"PMC_21825870","title":"Natural killer cells, dendritic cells, and the alarmin high-mobility group box 1 protein: a dangerous trio in HIV-1 infection?","date":"2011","source":"Current opinion in HIV and AIDS","url":"https://pubmed.ncbi.nlm.nih.gov/21825870","citation_count":20,"is_preprint":false},{"pmid":"35586607","id":"PMC_35586607","title":"Refinements and considerations for trio whole-genome sequence analysis when investigating Mendelian diseases presenting in early childhood.","date":"2022","source":"HGG advances","url":"https://pubmed.ncbi.nlm.nih.gov/35586607","citation_count":19,"is_preprint":false},{"pmid":"29507082","id":"PMC_29507082","title":"Trio sequencing in pediatric cancer and clinical implications.","date":"2018","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29507082","citation_count":19,"is_preprint":false},{"pmid":"29088317","id":"PMC_29088317","title":"Trio, a novel high fecundity allele: I. Transcriptome analysis of granulosa cells from carriers and noncarriers of a major gene for bovine ovulation rate.","date":"2018","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/29088317","citation_count":19,"is_preprint":false},{"pmid":"37828081","id":"PMC_37828081","title":"A de novo missense mutation in MPP2 confers an increased risk of Vogt-Koyanagi-Harada disease as shown by trio-based whole-exome sequencing.","date":"2023","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37828081","citation_count":18,"is_preprint":false},{"pmid":"25684408","id":"PMC_25684408","title":"Molecular evolution and expression of the CRAL_TRIO protein family in insects.","date":"2015","source":"Insect biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25684408","citation_count":18,"is_preprint":false},{"pmid":"33479664","id":"PMC_33479664","title":"Defeating the trypanosomatid trio: proteomics of the protozoan parasites causing neglected tropical diseases.","date":"2020","source":"RSC medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33479664","citation_count":18,"is_preprint":false},{"pmid":"29207149","id":"PMC_29207149","title":"Knockdown of Trio by CRISPR/Cas9 suppresses migration and invasion of cervical cancer cells.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/29207149","citation_count":17,"is_preprint":false},{"pmid":"29152845","id":"PMC_29152845","title":"Association of IMMP2L deletions with autism spectrum disorder: A trio family study and meta-analysis.","date":"2017","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29152845","citation_count":17,"is_preprint":false},{"pmid":"37679252","id":"PMC_37679252","title":"The cytokine trio - visfatin, placental growth factor and fractalkine - and their role in myocardial infarction with non-obstructive coronary arteries (MINOCA).","date":"2023","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/37679252","citation_count":16,"is_preprint":false},{"pmid":"25851347","id":"PMC_25851347","title":"Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25851347","citation_count":16,"is_preprint":false},{"pmid":"39443754","id":"PMC_39443754","title":"Gamma-Mobile-Trio systems are mobile elements rich in bacterial defensive and offensive tools.","date":"2024","source":"Nature microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/39443754","citation_count":16,"is_preprint":false},{"pmid":"29890989","id":"PMC_29890989","title":"Emerging roles of TRIO and F-actin-binding protein in human diseases.","date":"2018","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/29890989","citation_count":15,"is_preprint":false},{"pmid":"36990084","id":"PMC_36990084","title":"Trio RNA sequencing in a cohort of medically complex children.","date":"2023","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36990084","citation_count":15,"is_preprint":false},{"pmid":"35530959","id":"PMC_35530959","title":"Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6A modification of Trio mRNA.","date":"2022","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35530959","citation_count":15,"is_preprint":false},{"pmid":"34576329","id":"PMC_34576329","title":"The RhoGEF Trio: A Protein with a Wide Range of Functions in the Vascular Endothelium.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34576329","citation_count":14,"is_preprint":false},{"pmid":"37719664","id":"PMC_37719664","title":"Trio-based GWAS identifies novel associations and subtype-specific risk factors for cleft palate.","date":"2023","source":"HGG advances","url":"https://pubmed.ncbi.nlm.nih.gov/37719664","citation_count":14,"is_preprint":false},{"pmid":"34914033","id":"PMC_34914033","title":"RhoGEF Trio Regulates Radial Migration of Projection Neurons via Its Distinct Domains.","date":"2021","source":"Neuroscience bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/34914033","citation_count":14,"is_preprint":false},{"pmid":"22438988","id":"PMC_22438988","title":"Control of dendritic morphogenesis by Trio in Drosophila melanogaster.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22438988","citation_count":14,"is_preprint":false},{"pmid":"32366678","id":"PMC_32366678","title":"The Rho guanine nucleotide exchange factor Trio is required for neural crest cell migration and interacts with Dishevelled.","date":"2020","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32366678","citation_count":14,"is_preprint":false},{"pmid":"35963430","id":"PMC_35963430","title":"Autoinhibition of the GEF activity of cytoskeletal regulatory protein Trio is disrupted in neurodevelopmental disorder-related genetic variants.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35963430","citation_count":14,"is_preprint":false},{"pmid":"29415466","id":"PMC_29415466","title":"The Role of Trio, a Rho Guanine Nucleotide Exchange Factor, in Glomerular Podocytes.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29415466","citation_count":14,"is_preprint":false},{"pmid":"40131272","id":"PMC_40131272","title":"Diagnostic Utility of Trio-Exome Sequencing for Children With Neurodevelopmental Disorders.","date":"2025","source":"JAMA network open","url":"https://pubmed.ncbi.nlm.nih.gov/40131272","citation_count":13,"is_preprint":false},{"pmid":"30793229","id":"PMC_30793229","title":"Spindle cell liposarcoma with a TRIO-TERT fusion transcript.","date":"2019","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30793229","citation_count":13,"is_preprint":false},{"pmid":"35872089","id":"PMC_35872089","title":"Trio and Kalirin as unique enactors of Rho/Rac spatiotemporal precision.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35872089","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46581,"output_tokens":8420,"usd":0.133021,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18114,"output_tokens":5976,"usd":0.119985,"stage2_stop_reason":"end_turn"},"total_usd":0.253006,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Trio is essential for late embryonic development in mice; trio(-/-) embryos die between E15.5 and birth and display defects in secondary myogenesis (secondary myofibers absent, primary myofibers become aberrantly spherical) and aberrant organization in hippocampal and olfactory bulb regions, establishing Trio's roles in skeletal muscle formation and neural tissue organization.\",\n      \"method\": \"Mouse knockout (trio-/-), histology, genotype analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean loss-of-function mouse model with specific cellular phenotypes replicated across multiple tissues, published in a focused mechanistic study\",\n      \"pmids\": [\"11050238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The amino-terminal GEF domain of Trio (GEF1) induces membrane ruffling, rapid cell spreading, haptotactic migration, and anchorage-independent growth when stably expressed in NIH 3T3 cells; the carboxy-terminal GEF domain produces a distinct lamellar/mini-ruffle phenotype. Full-length Trio also alters actin cytoskeleton organization and focal contact distribution in COS cells.\",\n      \"method\": \"Stable cell line expression of individual GEF domains, actin staining, haptotaxis assay, soft-agar anchorage-independent growth assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal cellular assays in a single lab, no in vitro biochemical reconstitution\",\n      \"pmids\": [\"10341202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Trio mediates netrin-1-induced Rac1 activation via its interaction with the netrin-1 receptor DCC. Trio co-immunoprecipitates with DCC in mouse embryonic brains; Trio(-/-) cortical neurons fail to extend neurites in response to netrin-1; commissural axon guidance toward the floor plate is disrupted; anterior commissure is absent and netrin-1/DCC-dependent corpus callosum and internal capsule projections are defective in Trio-null embryos.\",\n      \"method\": \"Co-immunoprecipitation from embryonic brain, Trio(-/-) cortical neuron neurite outgrowth assay, spinal cord explant axon guidance assay, in vivo axon tract analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus multiple orthogonal loss-of-function assays (neuronal culture, explant, in vivo) in one study\",\n      \"pmids\": [\"18212043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Drosophila Trio physically interacts with the Netrin receptor Frazzled (Fra) in GST-pulldown and co-immunoprecipitation assays. Mutations in trio dominantly enhance fra and Netrin mutant CNS commissure phenotypes; fra;trio double mutants show dramatic loss of commissural axons. Tyrosine phosphorylation of Trio is elevated when Abl kinase levels are increased in S2 cells. Heterozygosity for trio reduces ectopic midline crossing in Robo-Fra chimeric receptor embryos, placing Trio as an effector of Fra/Netrin signaling.\",\n      \"method\": \"GST-pulldown, co-immunoprecipitation, genetic epistasis (double mutants, dominant enhancement), S2 cell phosphorylation assay\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — physical interaction confirmed by two methods (GST pulldown + Co-IP) combined with genetic epistasis across multiple allele combinations\",\n      \"pmids\": [\"15790972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The Rho-specific GEF domain of C. elegans UNC-73 (Trio ortholog) is a major Gαq effector. Forward genetic suppressor screens of hyperactive Gαq identified four mutations in the UNC-73 RhoGEF domain. UNC-73 RhoGEF loss phenocopies EGL-8 (PLCβ) loss (sluggish locomotion); double null of both genes phenocopies Gαq null (near-complete paralysis). Cell-based and biochemical assays show activated Gαq synergizes with Trio RhoGEF to activate RhoA, and activated Gαq co-immunoprecipitates with Trio RhoGEF.\",\n      \"method\": \"Forward genetic suppressor screen, double-mutant epistasis, cell-based Rho activation assay, co-immunoprecipitation, biochemical GEF assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — forward genetic screen + biochemical reconstitution + epistasis in one rigorous study\",\n      \"pmids\": [\"17942708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ITX3, identified by screening for inhibitors of Trio's N-terminal GEF domain (TrioN/GEF1), selectively blocks TrioN-mediated Rac1 activation and dorsal membrane ruffling in mammalian cells without affecting GEF337-, Tiam1-, or Vav2-mediated GTPase activation. ITX3 inhibits endogenous TrioN activity and blocks NGF-stimulated neurite outgrowth in PC12 cells and C2C12 myotube differentiation, defining a Trio/RhoG/Rac1 signaling pathway.\",\n      \"method\": \"Chemical inhibitor screen, Rac1 activation assay, cell morphology/ruffling assay, neurite outgrowth assay, myotube differentiation assay\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective small-molecule tool with multiple functional readouts in a single lab\",\n      \"pmids\": [\"19549603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Trio binds focal adhesion kinase (FAK) via its SH3 domain (to FAK N-terminal domain) and kinase domain (to FAK kinase domain). Trio is constitutively tyrosine-phosphorylated; co-expression with FAK increases Trio in the detergent-insoluble fraction and causes co-localization at the cell periphery. FAK phosphorylates Trio at Y2737 in the kinase domain subdomain I. Trio reciprocally enhances FAK kinase activity in vitro and in vivo.\",\n      \"method\": \"Co-precipitation/co-immunoprecipitation, immunofluorescence co-localization, in vitro kinase assay, co-transfection, site identification by phosphopeptide mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP + in vitro kinase assay in a single lab study\",\n      \"pmids\": [\"12551902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A Trio-RhoA-Shroom3 pathway is required for apical constriction during lens pit invagination. Rock activity and RhoA activity are required for Shroom3-induced apical constriction; Trio was identified as the RhoA-GEF required for Shroom3-dependent apical constriction in both MDCK cells and the lens pit in vivo.\",\n      \"method\": \"Dominant-negative/constitutively active RhoA constructs, siRNA knockdown, lens-specific in vivo studies, Rock inhibitor treatment, epistasis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown + constitutively active rescue + in vivo lens pit assay in a single lab\",\n      \"pmids\": [\"22031541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A Trio-Rac1-Pak1 signaling axis drives invadopodia disassembly. A genetically encoded single-chain Rac1 FRET biosensor showed Rac1 activity exclusion from invadopodia cores and activation at invadopodia disappearance; photoactivation of Rac1 at invadopodia confirmed its disassembly role. Trio (TrioGEF) activates Rac1, which activates Pak1, leading to cortactin phosphorylation and invadopodia dissolution.\",\n      \"method\": \"FRET biosensor (live-cell imaging), Rac1 photoactivation, siRNA knockdown, cortactin phosphorylation assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — FRET biosensor plus photoactivation plus biochemical phosphorylation readout; multiple orthogonal methods in one study\",\n      \"pmids\": [\"24859002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TRIO is phosphorylated at Y2681 by ABL tyrosine kinase downstream of a NOTCH-DAB1-ABL signaling cascade in colorectal cancer cells. pY2681 causes RHO activation; the unphosphorylatable TRIO Y2681F mutation reduces RHOGEF activity and inhibits invasion of colorectal cancer cells, establishing Trio as a downstream ABL substrate that transduces NOTCH signaling to RhoA-mediated invasion.\",\n      \"method\": \"Genetic depletion (knockout mice), phospho-specific antibody detection, unphosphorylatable mutant (Y2681F) functional assay, ABL inhibitor treatment, invasion assay\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — phospho-site identified, unphosphorylatable mutant used for functional rescue, in vivo genetic validation, multiple orthogonal approaches\",\n      \"pmids\": [\"25432929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Suppression of endogenous TRIO in dissociated rat hippocampal neurons enhances dendritic formation, and decreasing TRIO in organotypic hippocampal slices increases synaptic strength by increasing functional synapse number, demonstrating a direct role for Trio in dendritic branching and synapse development.\",\n      \"method\": \"siRNA knockdown in primary neurons, morphometric dendritic analysis, whole-cell electrophysiology in organotypic slices\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function in primary neurons with morphological and electrophysiological readouts, single lab\",\n      \"pmids\": [\"26721934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Trio and Kalirin play critical and redundant roles in excitatory synapse structure and function. CaMKII phosphorylation of Kalirin is sufficient to enhance synaptic AMPA receptor expression; preventing CaMKII signaling through Kalirin and Trio prevents LTP induction, placing Trio/Kalirin as the elusive CaMKII targets responsible for AMPA receptor upregulation during LTP.\",\n      \"method\": \"Molecular biology (dominant-negative/constitutively active constructs), electrophysiology (LTP recordings), imaging, biochemical phosphorylation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (electrophysiology + molecular + imaging) demonstrating epistatic relationship and sufficiency of CaMKII-Kalirin/Trio signaling for LTP\",\n      \"pmids\": [\"26858404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Trio interacts with VE-cadherin at endothelial adherens junctions and locally activates Rac1 during nascent junction formation. The Rac-GEF domain of Trio remodels junctional actin from radial to cortical bundles, promoting linear adherens junction formation and increasing endothelial monolayer resistance.\",\n      \"method\": \"Co-immunoprecipitation, FRET-based Rac1 biosensor, siRNA knockdown, electrical resistance measurement, actin imaging\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP + FRET biosensor + functional barrier assay, single lab\",\n      \"pmids\": [\"26116572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Trio interacts with peptidylglycine alpha-amidating monooxygenase (PAM), a secretory granule membrane protein. Cdk5-mediated phosphorylation of Trio (at consensus Cdk5 sites) is required for Trio-dependent Rac activation; roscovitine (Cdk5 inhibitor) inhibits Trio-mediated Rac activation, reorganizes cortical actin, and limits secretory granule approach to the plasma membrane, impairing hormone exocytosis.\",\n      \"method\": \"Protein interaction (co-IP with PAM), in vitro Cdk5 phosphorylation assay, Rac activation assay, roscovitine pharmacological inhibition, ultrastructural analysis\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay + Rac activation assay + pharmacological perturbation with functional secretion readout, single lab\",\n      \"pmids\": [\"15331630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Trio mediates HOXC8-dependent CDH11 (cadherin 11)-stimulated breast cancer cell migration by activating Rac1. CDH11 physically interacts with Trio and recruits Trio to the plasma membrane where Trio activates Rac, enabling actin ruffle formation and migration; CDH11 knockdown prevents plasma membrane localization of Trio.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, Rac1 activation assay, actin staining, migration assay, immunofluorescence localization\",\n      \"journal\": \"Genes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP + localization + Rac activation + migration assay, single lab\",\n      \"pmids\": [\"22593800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Trio acts as the Rac1-activating GEF downstream of the TWEAK-Fn14 signaling axis in glioblastoma cells. Trio depletion inhibits TWEAK-induced Rac1 activation but not Cdc42 activation, and abrogates TWEAK-Fn14-directed glioma cell migration and invasion, while Ect2 depletion blocks both Cdc42 and Rac1 activation.\",\n      \"method\": \"siRNA knockdown, Rac1/Cdc42 activation assays, migration/invasion assays (Boyden chamber), in vivo RCAS gene transfer model\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective siRNA knockdown with GTPase activation assays and functional migration readouts, single lab\",\n      \"pmids\": [\"22571869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Hsc70 (heat shock cognate protein 70) dynamically associates with the N-terminal region and Rac1 GEF domain of Trio, supporting Trio-dependent Rac1 activation. ATPase-deficient Hsc70 (D10N) abrogates Trio Rac1 GEF activity and netrin-1-induced Rac1 activation. Hsc70 is required for netrin-1-mediated axon growth and attraction in vitro and supports callosal projections and radial neuronal migration in the embryonic neocortex.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative Hsc70 (D10N) expression, Rac1 activation assay, in vitro axon growth assay, in vivo neuronal migration assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP + dominant-negative + Rac1 activation + in vivo migration assay, single lab\",\n      \"pmids\": [\"26323693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RhoG and its exchange factor Trio regulate circular dorsal ruffle (CDR) dynamics, macropinocytosis, receptor internalization, and cell migration. RhoG is activated by Trio downstream of PDGF in a PI3K- and Src-dependent manner. Silencing RhoG decreases CDR number and area independently of Rac1.\",\n      \"method\": \"siRNA knockdown, GTPase activation assay, CDR live-cell imaging, macropinocytosis assay, pharmacological inhibitors (PI3K, Src)\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown + activation assay + multiple functional readouts, single lab\",\n      \"pmids\": [\"28468978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TRIO localizes to the Golgi in mouse cerebellar granule neurons and regulates directional membrane trafficking by controlling RAB8- and RAB10-positive vesicle maintenance. The spectrin repeats of Golgi-resident TRIO interact with and activate the RAB GEF RABIN8, thereby activating RAB8 and RAB10. Constitutively active RAB8 or RAB10 partially restores neurite outgrowth in TRIO-deficient neurons.\",\n      \"method\": \"Co-localization (immunofluorescence), live-cell imaging, FRAP, co-immunoprecipitation, RAB8/RAB10 activation assay, TRIO knockout neuronal rescue experiment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, live imaging, FRAP, functional rescue) in a single lab\",\n      \"pmids\": [\"31152060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Trio haploinsufficiency in excitatory neurons causes increased anxiety, impaired social preference, reduced forebrain size, reduced dendritic arborization, increased dendritic spine density, and failure of LTP. PDE4A5 levels are reduced and PKA signaling is increased when TRIO is reduced; elevation of PDE4A5 or attenuation of PKA signaling rescues dendritic spine defects, placing Trio upstream of a PDE4A5-PKA pathway.\",\n      \"method\": \"Conditional neuron-specific Trio knockout (Cre-lox), behavioral tests, spine morphometry, electrophysiology (LTP), Western blot, pharmacological rescue\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with behavioral, structural, electrophysiological, and biochemical readouts plus pharmacological rescue in one study\",\n      \"pmids\": [\"30840899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ASD/ID-related Trio mutation D1368V (in GEF1 domain) produces pathological increase in glutamatergic synaptogenesis; Trio N1080I (in spectrin repeat 8) inhibits Trio's interaction with Neuroligin 1 (NLGN1) and prevents Trio D1368V-mediated synaptogenesis. Trio interacts with NLGN1 in the brain, and this interaction is required for NLGN1-mediated NMDA receptor (but not AMPA receptor) synaptic function.\",\n      \"method\": \"Co-immunoprecipitation from brain, super-resolution spine imaging, whole-cell voltage-clamp electrophysiology in hippocampal slices, molecular biology (mutant constructs)\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP from native brain tissue + mutagenesis + super-resolution imaging + electrophysiology; multiple orthogonal methods\",\n      \"pmids\": [\"34353896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Synaptic proteomics revealed that Trio interacts with axon guidance and presynaptic complexes (distinct from Kalirin-7 which associates more with synaptic adhesion molecules). These differential interactomes were established by unbiased AP-MS proteomics.\",\n      \"method\": \"Unbiased affinity purification mass spectrometry (AP-MS) proteomics\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — unbiased proteomics identifying distinct interactomes, single lab\",\n      \"pmids\": [\"31801062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The GEF1 domain of Trio and activation of Rac1 and RhoG in the cell periphery are required for VEGF-signaling-dependent enlargement of arterial endothelial cells, driving large-caliber artery formation in zebrafish and cell models. This involves F-actin remodeling, myosin-based tension at junctions, and focal adhesions. Vegf signaling strength is titrated by soluble Flt1 to control Trio activity.\",\n      \"method\": \"Zebrafish embryo genetics (morpholino/mutant), GEF1-domain-specific Trio constructs, endothelial cell models, actin imaging, focal adhesion analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo zebrafish + cell model with domain-specific constructs, single lab\",\n      \"pmids\": [\"33087700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Trio conditional knockout in excitatory cortical/hippocampal neurons causes aberrant polarity and halted migration of late-born pyramidal neurons. The Trio N-terminal SH3 domain interacts with Myosin X, mediating adherence of migrating neurons to radial glial fibers by regulating N-cadherin membrane localization. Independent or synergistic overexpression of RAC1 and RHOA produces different phenotypic recoveries, demonstrating distinct roles of GEF1 (RAC1) and GEF2 (RHOA) domains in radial migration.\",\n      \"method\": \"Conditional knockout, in utero electroporation, immunofluorescence, Co-IP (SH3-Myosin X), N-cadherin membrane localization assay, rescue with constitutively active RAC1/RHOA\",\n      \"journal\": \"Neuroscience bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO + Co-IP + domain-specific rescue, single lab\",\n      \"pmids\": [\"34914033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Spectrin repeats (SRs) 6-9 of Trio interact intramolecularly with the GEF1 domain to autoinhibit its catalytic activity both in vitro and in cells. NDD-associated variants in SR8 and GEF1 domain relieve this autoinhibitory constraint. Chemical cross-linking and bio-layer interferometry indicate SRs primarily contact the pleckstrin homology region of GEF1, reducing GEF1 binding to Rac1.\",\n      \"method\": \"In vitro GEF activity assay, cell-based Rac1 activation assay, chemical cross-linking mass spectrometry, bio-layer interferometry, NDD variant mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of autoinhibition + structural mapping by cross-linking MS + bio-layer interferometry + cell-based validation; multiple Tier 1-2 methods in single study\",\n      \"pmids\": [\"35963430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TRIO is amplified and overexpressed in urinary bladder cancer and soft tissue sarcomas; TRIO amplification strongly associates with invasive tumor phenotype, high tumor grade, and rapid cell proliferation (Ki67). However, these are correlative findings — no direct mechanistic experiment was performed in this paper.\",\n      \"method\": \"FISH on tissue microarray, RNA in situ hybridization\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — purely correlative genomic/expression analysis with no direct mechanistic experiment on Trio protein function\",\n      \"pmids\": [\"15215162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ALKBH5, an m6A RNA demethylase, is downregulated during myocardial ischemia/reperfusion injury (MIRI). MeRIP-seq and RNA-seq in ALKBH5-overexpressed HL-1 cells identified Trio mRNA as a target whose m6A modification level is increased when ALKBH5 is lost, leading to decreased Trio expression. Overexpression of ALKBH5 is protective against MIRI-related cell injury and apoptosis.\",\n      \"method\": \"MeRIP-seq, RNA-seq, MeRIP-qPCR, siRNA/overexpression, cell viability/apoptosis assays\",\n      \"journal\": \"Annals of translational medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — methylation sequencing identifies Trio mRNA as m6A target but functional link between Trio m6A modification and MIRI is inferred rather than directly demonstrated with Trio-specific rescue\",\n      \"pmids\": [\"35530959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Trio interacts with ANKRD26 protein (identified by yeast two-hybrid and immunoprecipitation). Selective knockdown of Trio increases adipogenesis in 3T3-L1 cells, establishing Trio as a regulator of adipogenesis.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, adipogenesis assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast two-hybrid + single Co-IP + knockdown phenotype; single lab, limited mechanistic follow-up\",\n      \"pmids\": [\"22666460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Trio is expressed in glomerular podocytes and activates basal Rac1 activity. Reduced Trio expression in cultured human podocytes decreases basal Rac1 activity, cell size, laminin attachment, and motility. TGFβ1 increases Rac1 activity in control cells but decreases it in Trio-knockdown cells (attributed to simultaneous CdGAP activation).\",\n      \"method\": \"siRNA knockdown, Rac1 activation assay, cell size/adhesion/motility assays, RNA-seq expression profiling\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — knockdown + Rac1 activation assay in cultured cells, single lab, limited mechanistic depth\",\n      \"pmids\": [\"29415466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Trio gene deletion in EMX1-Cre mice (brain cortex and hippocampus) results in smaller brains, abnormal hippocampal structure, and disordered granule cells in DG and CA regions. EMX1-Trio(-/-) mice show impaired hippocampal-dependent spatial learning, establishing Trio's role in adult hippocampal-dependent learning.\",\n      \"method\": \"Conditional knockout (EMX1-Cre), brain morphology analysis, behavioral tests (spatial learning/Morris water maze)\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined hippocampal phenotype and behavioral readout, single lab\",\n      \"pmids\": [\"25727174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Trio is required for Xenopus cranial neural crest cell migration and cartilage formation. Trio cell-autonomously controls protrusion formation; Trio GEF2 domain is sufficient to rescue protrusion and migration defects. The Trio GEF2 domain interacts with the DEP/C-terminus of Dishevelled (DVL), and DVL rescues Rac1 activity and protrusion formation in Trio morphant embryos, defining a Trio-DVL-Rac1 pathway in neural crest migration.\",\n      \"method\": \"Morpholino knockdown in Xenopus, rescue with domain-specific constructs, Co-IP (Trio GEF2 - DVL), Rac1 activation assay, live-cell imaging of protrusions\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — morpholino knockdown + domain-specific rescue + Co-IP + Rac1 activation; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"32366678\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TRIO is a multidomain Rho guanine nucleotide exchange factor (RhoGEF) containing two catalytic GEF domains (GEF1 activates Rac1/RhoG; GEF2 activates RhoA), a serine/threonine kinase domain, spectrin repeats, SH3 domains, and other scaffolding domains; the spectrin repeats 6-9 autoinhibit GEF1 activity by contacting its PH region, and NDD-associated mutations relieve this constraint. Trio is activated downstream of cell-surface receptors including the netrin receptor DCC (mediating Rac1-dependent axon guidance), Gαq-coupled receptors (activating RhoA together with PLCβ), VEGFR (driving arterial remodeling), and the NOTCH-DAB1-ABL axis (via ABL-mediated phosphorylation at Y2681 to activate RhoA in cancer invasion). Trio interacts physically with FAK, VE-cadherin, Neuroligin-1, Hsc70, Myosin X, RABIN8 (activating RAB8/RAB10 from the Golgi), and ANKRD26. In neurons, CaMKII phosphorylates the Trio paralog Kalirin (and redundantly Trio) to drive AMPA receptor upregulation and LTP; Trio also controls radial migration, dendritic branching, synapse formation, and spatial learning via Rac1 and RhoA, while at non-neuronal sites it regulates endothelial barrier integrity, apical constriction, invadopodia disassembly, and exocytosis through context-specific GTPase activation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TRIO is a multidomain Rho-family guanine nucleotide exchange factor that couples cell-surface receptor signaling to actin cytoskeletal remodeling, governing axon guidance, neuronal migration, synapse formation, and morphogenetic cell movements [#0, #2]. Its two catalytic GEF domains are functionally specialized: the N-terminal GEF1 domain activates Rac1 (and RhoG) to drive membrane ruffling, spreading, and migration, while the C-terminal GEF2 domain activates RhoA, and these activities can be experimentally separated by domain-specific constructs and the GEF1-selective inhibitor ITX3 [#1, #5, #23]. GEF1 catalytic output is held in check by an intramolecular autoinhibitory contact in which spectrin repeats 6-9 engage the GEF1 pleckstrin-homology region to reduce Rac1 binding; neurodevelopmental-disorder variants in SR8 and GEF1 relieve this constraint, and the GEF1 mutation D1368V drives pathological glutamatergic synaptogenesis [#24, #20]. TRIO is deployed downstream of multiple receptors through distinct adaptors: it binds the netrin receptor DCC/Frazzled to mediate Rac1-dependent commissural axon guidance and neurite outgrowth [#2, #3], acts as a major Gαq effector that synergizes with PLCβ to activate RhoA [#4], and is recruited by VE-cadherin, CDH11, the TWEAK-Fn14 axis, and VEGF/Flt1 signaling to control endothelial junctions, tumor cell migration, and arterial caliber via local Rac1/RhoG activation [#12, #14, #15, #22]. TRIO function is tuned by phosphorylation—by FAK at Y2737, by Cdk5, and by ABL at Y2681 downstream of a NOTCH-DAB1-ABL cascade that promotes RhoA-driven cancer invasion [#6, #13, #9]. In the nervous system TRIO and its paralog Kalirin act redundantly as the CaMKII targets required for synaptic AMPA receptor upregulation during LTP, and TRIO controls dendritic branching, synapse number, radial migration, and spatial learning, with conditional loss producing reduced forebrain size, spine and LTP deficits, and a PDE4A5-PKA signaling imbalance [#11, #10, #19, #29]. TRIO additionally scaffolds membrane trafficking through Hsc70 and a Golgi-localized spectrin-repeat interaction with RABIN8 that activates RAB8/RAB10, and engages Myosin X via its SH3 domain to regulate N-cadherin-dependent adhesion during migration [#16, #18, #23]. Beyond neurons, GEF1-driven Rac1 activation directs invadopodia disassembly and apical constriction during epithelial morphogenesis [#8, #7].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that Trio's two GEF domains are functionally distinct effectors of cytoskeletal change, with GEF1 driving ruffling/migration/transformation and GEF2 a separate lamellar phenotype.\",\n      \"evidence\": \"Stable expression of individual GEF domains in NIH 3T3/COS cells with actin staining, haptotaxis, and soft-agar growth assays\",\n      \"pmids\": [\"10341202\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro biochemical reconstitution of GEF activity\", \"GTPase specificity of each domain not directly defined here\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined Trio as essential in vivo, linking it to skeletal muscle formation and neural tissue organization through a loss-of-function embryonic phenotype.\",\n      \"evidence\": \"Constitutive trio-/- mouse knockout with histology across muscle and brain\",\n      \"pmids\": [\"11050238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which GEF domain or GTPase mediates each tissue defect\", \"Cell-autonomous vs non-autonomous mechanism unaddressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed Trio is integrated with focal adhesion signaling, binding and reciprocally activating FAK and being phosphorylated at Y2737.\",\n      \"evidence\": \"Reciprocal Co-IP, immunofluorescence co-localization, in vitro kinase assay and phosphopeptide mapping\",\n      \"pmids\": [\"12551902\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of Y2737 phosphorylation for GEF activity not established\", \"Single-lab in vitro kinase data\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected Trio to regulated exocytosis, showing Cdk5 phosphorylation gates Trio-dependent Rac activation and secretory granule trafficking.\",\n      \"evidence\": \"Co-IP with PAM, in vitro Cdk5 kinase assay, Rac activation assay, roscovitine inhibition with ultrastructural readout\",\n      \"pmids\": [\"15331630\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cdk5 phosphosites not mapped to functional residues\", \"Pharmacological Cdk5 inhibition not isoform-specific\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Placed Trio genetically downstream of Netrin/Frazzled axon guidance and as an ABL phosphorylation target in Drosophila.\",\n      \"evidence\": \"GST-pulldown, Co-IP, genetic epistasis across allele combinations, S2 cell phosphorylation\",\n      \"pmids\": [\"15790972\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which GTPase mediates Frazzled output not resolved in this study\", \"ABL phosphosite not mapped here\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified the Trio/UNC-73 RhoGEF domain as a major Gαq effector activating RhoA in synergy with PLCβ, defining a parallel Gq output.\",\n      \"evidence\": \"Forward genetic suppressor screen, double-mutant epistasis, cell-based and biochemical Rho activation assays, Co-IP in C. elegans\",\n      \"pmids\": [\"17942708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mammalian Gαq-Trio biochemistry not shown here\", \"Structural basis of Gαq-RhoGEF synergy unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated Trio physically links the netrin receptor DCC to Rac1 activation required for commissural axon guidance in mammals.\",\n      \"evidence\": \"Co-IP from embryonic brain, Trio-/- neurite/explant guidance assays, in vivo axon tract analysis\",\n      \"pmids\": [\"18212043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of DCC-induced Trio activation not defined\", \"Role of GEF2/RhoA in guidance unaddressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Provided a selective chemical tool (ITX3) confirming a discrete Trio/RhoG/Rac1 pathway controlling neurite outgrowth and myotube differentiation.\",\n      \"evidence\": \"Inhibitor screen against TrioN/GEF1, Rac1 activation, ruffling, neurite and myotube differentiation assays\",\n      \"pmids\": [\"19549603\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Off-target profile beyond tested GEFs not exhaustive\", \"In vivo efficacy not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established Trio as the RhoA-GEF executing Shroom3-driven apical constriction during epithelial invagination.\",\n      \"evidence\": \"siRNA, dominant-negative/constitutively active RhoA, Rock inhibition, in vivo lens pit assay\",\n      \"pmids\": [\"22031541\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How Shroom3 recruits/activates Trio not defined\", \"Single-lab knockdown evidence\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended Trio's Rac1-GEF role to cancer cell migration via CDH11- and TWEAK-Fn14-dependent recruitment and ANKRD26 binding in adipogenesis.\",\n      \"evidence\": \"Co-IP, yeast two-hybrid, siRNA, Rac1/Cdc42 activation, migration/invasion and adipogenesis assays across studies\",\n      \"pmids\": [\"22593800\", \"22571869\", \"22666460\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ANKRD26 interaction limited to Y2H plus single Co-IP\", \"Receptor-to-Trio activation mechanisms not fully reconstituted\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined opposing roles for Trio-Rac1 in actin structures—driving invadopodia disassembly—and identified ABL phosphorylation of Y2681 downstream of NOTCH-DAB1 as a switch for RhoA-driven invasion.\",\n      \"evidence\": \"Rac1 FRET biosensor and photoactivation; phospho-specific antibody, Y2681F mutant rescue, ABL inhibition, invasion assays\",\n      \"pmids\": [\"24859002\", \"25432929\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural effect of Y2681 phosphorylation on GEF2 unknown\", \"Interplay of GEF1 and GEF2 outputs in the same cell not reconciled\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified Trio (redundant with Kalirin) as the long-sought CaMKII target driving AMPA receptor upregulation during LTP, while also controlling dendritic branching, synapse number, and spatial learning.\",\n      \"evidence\": \"LTP electrophysiology with dominant-negative/CA constructs, siRNA in primary neurons, organotypic slice physiology, conditional EMX1-Cre KO behavior\",\n      \"pmids\": [\"26858404\", \"26721934\", \"25727174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CaMKII phosphosite on Trio not mapped here\", \"GTPase identity downstream of CaMKII-Trio for AMPAR insertion not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed Trio engages additional partners—VE-cadherin at endothelial junctions and the chaperone Hsc70—to spatially control Rac1 activation in junction formation, axon growth, and neuronal migration.\",\n      \"evidence\": \"Co-IP, Rac1 FRET biosensor, ATPase-dead Hsc70 D10N, barrier resistance, axon growth and in vivo migration assays\",\n      \"pmids\": [\"26116572\", \"26323693\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How Hsc70 ATPase cycle gates GEF1 catalysis mechanistically unclear\", \"Single-lab Co-IP evidence for each interaction\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established Trio-RhoG signaling downstream of PDGF/PI3K/Src controls dorsal ruffle dynamics, macropinocytosis, and receptor internalization independently of Rac1.\",\n      \"evidence\": \"siRNA, GTPase activation, CDR/macropinocytosis live imaging, PI3K/Src inhibitors\",\n      \"pmids\": [\"28468978\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical link from PDGFR to Trio not shown\", \"RhoG vs Rac1 separation incomplete\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed Trio scaffolding of membrane trafficking via Golgi RABIN8-RAB8/RAB10 activation and distinct synaptic interactomes, and clarified its haploinsufficiency phenotype via a PDE4A5-PKA axis.\",\n      \"evidence\": \"Co-IP, FRAP, RAB8/RAB10 activation and rescue, AP-MS proteomics, conditional KO with behavior, LTP, spine morphometry and pharmacological rescue\",\n      \"pmids\": [\"31152060\", \"31801062\", \"30840899\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How GEF activity and RABIN8 scaffolding are coordinated unclear\", \"Mechanism linking Trio to PDE4A5 levels not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined GEF-domain-specialized roles in tissue morphogenesis: GEF1/Rac1-RhoG in VEGF-driven arterial caliber, and GEF2-RhoA via Dishevelled in neural crest migration.\",\n      \"evidence\": \"Zebrafish and Xenopus genetics, domain-specific rescue, Co-IP (GEF2-DVL), Rac1 activation, actin/protrusion imaging\",\n      \"pmids\": [\"33087700\", \"32366678\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor-proximal activation of each GEF domain not reconstituted\", \"Cross-talk between GEF1 and GEF2 in same tissue unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mapped a spectrin-repeat/Neuroligin-1 interaction controlling NMDA-receptor synaptic function and showed GEF1 variant D1368V drives pathological synaptogenesis blocked by an SR8 variant disrupting NLGN1 binding.\",\n      \"evidence\": \"Brain Co-IP, super-resolution spine imaging, voltage-clamp electrophysiology, mutant constructs\",\n      \"pmids\": [\"34353896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NLGN1 binding regulates GEF1 catalytic output mechanistically unclear\", \"Selectivity for NMDA over AMPA function not fully explained\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved the autoinhibitory architecture: spectrin repeats 6-9 contact the GEF1 PH region to suppress Rac1 binding, and NDD variants relieve this constraint—providing a unifying mechanism for disease mutations.\",\n      \"evidence\": \"In vitro and cell-based GEF assays, cross-linking MS, bio-layer interferometry, NDD variant mutagenesis\",\n      \"pmids\": [\"35963430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution structure of the autoinhibited state lacking\", \"How upstream receptors physically relieve autoinhibition unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How distinct upstream receptors selectively relieve GEF1 autoinhibition and choose between GEF1/Rac1 and GEF2/RhoA outputs within a single cell remains unresolved.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of receptor-triggered de-repression\", \"Coordination of GEF1 vs GEF2 activity in shared contexts undefined\", \"Direct in vivo requirement of each phosphosite (Y2737, Y2681, Cdk5 sites) not dissected together\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005085\", \"supporting_discovery_ids\": [1, 4, 24]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 24]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 4]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [18, 23]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 12, 14]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [1, 8, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 4, 9]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 2, 22, 30]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [11, 19, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"DCC\", \"FAK\", \"VE-cadherin\", \"NLGN1\", \"Hsc70\", \"RABIN8\", \"MYO10\", \"DVL\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}